I N V E S T O R S & M E D I A
Skinap Therapeutics is a clinical biopharmaceutical company committed to developing medicines and medical devices for life-threatening and non-healing wounds and tissue failure diseases.
Skinap has a portfolio of novel product candidates targeting large-area and severe wounds, SAST2. Skinap’s lead program, supermembrane (Skinap-278), is in approaching phase I clinical development for life-threatening wounds.
Skinap is developing its next generation of modulators, including Skinap-176 and Skinap-352, in various wounds and tissue failure diseases.
Investor inquiries: info@skinapus.com
Media inquiries: media@skinapus.com
Skinap Therapeutics Inc.
Address: 790 Memorial Drive
Address: 790 Memorial Drive
Cambridge, MA 02139
Email Us For More Information: info@skinapus.com